Top Markets
Coin of the day
Impact BioMedical Inc. Impact BioMedical Inc.

Impact BioMedical Inc.

IBO
Pozycja w akcjach #25450
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on... Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Cena akcji
$0.4587
Ostatnia synchronizacja: 2026-08-20
Kapitalizacja rynkowa
$49.46M
Zmiana (1 dzień)
5.89%
Zmiana (1 rok)
-22.83%
Kraj
US
Handel Impact BioMedical Inc. (IBO)

Kategoria

Zyski dla Impact BioMedical Inc. (IBO)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Impact BioMedical Inc., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Impact BioMedical Inc. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$-3.09B -
US